Literature DB >> 33389405

Metabolic Syndrome: does this influence breast cancer outcomes in the triple-negative population?

Kaitlyn Kennard1, Meghan E Buckley2, Lina M Sizer3, Sharon Larson2, William B Carter3, Thomas G Frazier3, Ned Z Carp4.   

Abstract

INTRODUCTION: Metabolic syndrome (MS) is defined by having at least 3 of 4 components: obesity, dyslipidemia, hypertension (HTN), and diabetes. Prior studies analyzed the individual components of MS for all breast cancers which are predominantly hormone positive. Our study is the first to evaluate MS in triple-negative breast cancer (TNBC).
METHODS: A retrospective review of TNBC from 2007 to 2013 identified 177 patients with complete information for statistical analysis. Cox proportional hazards models were used to test the association between MS, disease-free survival (DFS), and overall survival (OS).
RESULTS: 48 (27%) patients had MS. After controlling for age, race, pathologic stage, surgery type, and additional comorbidities outside of MS, MS was significantly associated with poorer DFS (adjusted HR: 2.24, p = 0.030), but not associated with OS (adjusted HR: 1.92, p = 0.103). HTN was significantly associated with poorer DFS (adjusted HR: 3.63, p = 0.006) and OS (adjusted HR: 3.45, p = 0.035) in the univariable and multivariable analyses. Diabetes was not associated with worse OS or DFS. The 5-year age-adjusted OS rates for 60-year-old patients with and without diabetes were 85.8% and 87.3%, respectively. The age-adjusted 5-year OS rate for 60-year old patients was higher in patients with a body mass index (BMI) > 30 (90.2%) versus BMIs of 25-29.9 (88.2%) or < 25 (83.5%).
CONCLUSION: In the TNBC population, MS was significantly associated with poorer DFS, but not associated with OS. HTN was the only component of MS that was significantly associated with both DFS and OS. Obesity has a potential small protective benefit in the TNBC population.

Entities:  

Keywords:  Breast cancer; Hypertension; Metabolic syndrome; Obesity; TNBC; Triple-negative breast cancer

Mesh:

Year:  2021        PMID: 33389405     DOI: 10.1007/s10549-020-06034-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  2 in total

1.  Regional differences in the prevalence of the metabolic syndrome in primary care practices in Germany.

Authors:  Susanne Moebus; Jens Hanisch; Peter Bramlage; Christian Lösch; Hans Hauner; Jürgen Wasem; Karl-Heinz Jöckel
Journal:  Dtsch Arztebl Int       Date:  2008-03-21       Impact factor: 5.594

2.  A Comparison of the Prevalence of the Metabolic Syndrome among Sri Lankan Patients with Type 2 Diabetes Mellitus Using WHO, NCEP-ATP III, and IDF Definitions.

Authors:  H M M Herath; N P Weerasinghe; T P Weerarathna; A Amarathunga
Journal:  Int J Chronic Dis       Date:  2018-08-07
  2 in total
  2 in total

1.  Preoperative Metabolic Syndrome and HDL-C Level Predict the Prognosis of Patients Following Radical Cystectomy: A Propensity Score Matching Study.

Authors:  Zenan Liu; Hai Bi; Wei He; Xuehua Zhu; Jide He; Min Lu; Jian Lu
Journal:  Front Oncol       Date:  2022-04-05       Impact factor: 5.738

2.  YAP Dictates Mitochondrial Redox Homeostasis to Facilitate Obesity-Associated Breast Cancer Progression.

Authors:  Jia-Zih Dai; Yen-Ju Wang; Cheng-Hsun Chen; I-Lin Tsai; Yi-Chun Chao; Cheng-Wei Lin
Journal:  Adv Sci (Weinh)       Date:  2022-02-18       Impact factor: 17.521

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.